On 28 April 2022, Mycovia (Viamet’s successor company) announced the approval from the US FDA of VIVJOA™ for the treatment of RVVC in females with a history of RVVC and who are not of reproductive potential.
Mycovia is planning its commercial launch of VIVJOA™ in the second quarter of 2022. The approval of VIVJOA™ will result in the initiation of recurring cash inflows to Malin from milestone payments and royalties.
Visit Mycovia’s website to learn more about VIVJOA™ and the company’s pipeline.
Candidate |
Indication |
IND-enabling |
Phase 1 |
Phase 2 |
Phase 3 |
Approved |
|---|---|---|---|---|---|---|
VT-1161 (VIVJOA™) |
Recurrent vulvovaginal candidiasis |
|||||
VT-1161 |
Onychomycosis |
|||||
VT-1598 |
Cryptococcal meningitis |
|
Candidate: VT-1161 (VIVJOA™) Indication: Recurrent vulvovaginal candidiasis |
||||
IND-enabling |
Phase 1 |
Phase 2 |
Phase 3 |
Approved |
|---|---|---|---|---|
|
Candidate: VT-1161 Indication: Onychomycosis |
||||
IND-enabling |
Phase 1 |
Phase 2 |
Phase 3 |
Approved |
|
Candidate: VT-1129 Indication: Cryptococcal meningitis |
||||
IND-enabling |
Phase 1 |
Phase 2 |
Phase 3 |
Approved |